LCT and nasopharyngeal carcinoma: Furthermore, Lac-β-CyD had a weak interaction with cholesterol (Figure 7a) and low cytotoxicity in NPC-like liver cells (Figure 7c), suggesting that Lac-β-CyD is a safer drug candidate for NPC treatment.